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1. Introduction 
Approximately 25,000 patients undergo renal transplantation every year worldwide due to 
end-stage renal disease(ESRD). Renal transplantation is expected to lead to a progressive 
correction of the established renal bone disease, and osteonecrosis of the femoral 
head(ONFH) is a common and severe complication in these patients. It induces deformity of 
the hip joint and reduces the quality of life, especially in the young population ranging from 
20 to 50 years old. Total hip replacement is not reasonable in this population due to the finite 
lifespan of implants. Clinical results suggest that free vascularized fibular grafting(FVFG) 
can slow or potentially halt the progression of osteonecrosis, it offers an alternative method 
for preserving the femoral head in younger renal transplant recipients. 
2. Clinical backgroud 
Chronic renal failure(CRF) and end-stage renal disease(ESRD) are associated with many 
disturbances of bone structure and metabolism due to deficiency of calcitriol, hypocalcemia, 
retention of phosphate, metabolic acidosis, secondary hyperparathyroidism. Renal 
transplantation can improve the metabolism disturbances of ESRD, but osseous 
complications like osteoporosis, consequent fracture, bone pain and osteonecrosis are not 
rare. It is reported that up to 40% of renal graft recipients have spontaneous osteoporotic 
pain. A major obstacle to the investigation of renal osteodystrophy in transplant recipients 
has been its unpredictable evolution under the multiple biochemical and hormonal 
influences that regulate mineral metabolism and bone turnover independently. Its course 
after transplantation depends on persisting abnormalities such as hypercalcaemia, 
hypophosphataemia and hypomagnesaemia as well as on the type, dose and duration of 
immunosuppressive medications that are needed to minimize allograft rejection.  
2.1 Morbidity of ONFH in the recipients 
Osteonecrosis of the femoral head (ONFH), an aseptic and ischemic disease, is especially 
common in the transplant recipients. Kubo documented femoral head MRI abnormalities of 
osteonecrosis in 25% of 51 renal allograft recipients; Marston reported 20% of 52 patients and 
11% of 103 hips developed ONFH within 1 year after transplantation; Lopez-Ben reported 4% 
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of 48 patients and three of 96 hips had ONFH within 6 months after renal transplantation; In 
the study of Lee, ONFH developed in 6.3% of the 237 patients and 4.9% of the 473 femoral 
heads from 8 months to 16 months after renal transplantation. In the report of Children by 
Nishiyama et al, 141 renal transplants were performed in 129 children(72 boys and 57 girls), 
aged from 2 to 17 years. Osteonecrosis occurred in seven patients, in the following sites: the 
femoral head in four children including two bilateral cases: and the femoral condyle in Three 
children, with two bilateral cases. The mean period from transplantation to the diagnosis of 
OHFH was 18 months, 75% appeared more than 9 months after transplantation.  
2.2 Etipathogenesis 
2.2.1 Use of corticosteroids 
High doses of corticosteroids are used after renal transplantation to reduce rejection and 
improve graft survival. They have also been implicated as the major predisposing factor for 
post-transplant bone loss and osteonecrosis, and It takes a few years to develop 
osteonecrosis after the start of corticosteroids therapy. Although corticosteroids therapy 
represents a pathogenetic key factor other immunosuppressive drugs such as cyclosporine, 
tacrolimus, azathioprine and rapamycin clearly contribute to its prevalence and expression 
through their pleiotropic pharmacological effects. These drugs have been shown to increase 
overall bone turnover and/or to stimulate loss of bone mass independently. Long-term 
glucocorticoid administration and possibly cyclosporine treatment may chronically activate 
osteoclasts in spongy and/or cortical bone while osteoblast activity is inhibited, and the 
highest tertiles of cumulative glucocorticoid were significantly associated with BMD loss 
and osteonecrosis. A prospective study using MRI in renal transplant patients showed the 
occurrence of ONFH within several months after the initiation of steroid treatment, and a 
time discrepancy between the occurrence of ONFH and onset of symptom.  
2.2.2 Dose-related risk of osteonecrosis 
Furthermore, an appreciable dose-related risk of osteonecrosis was also found in patients 
receiving long-term steroid therapy. Hirota et al reported the relationship between ONFH 
and the daily dosage of steroid (#16.6 mg in terms of prednisolone) or the highest daily dose 
(#80mg in terms of prednisolone) and concluded that higher steroid dosage per day 
contributed to increasing the frequency of ONFH in renal transplant patients. In a 
retrospective study of the medical records of 750 patients who had received a renal 
transplant during the period of 1968-1995, Lausten showed an 11.2% incidence of 
symptomatic osteonecrosis with high-dose glucocorticoids(cumulative mean dose of 
prednisolone 12.5g at 1 year post-transplant) and 5.1% with low-dose(cumulative mean dose 
of prednisolone average dose 6.5g). This difference in numbers of femoral head necroses 
was highly significant (p < 0.005); The cohort of Kopecky et al showed an osteonecrosis 
incidence of 22%, had a prednisolone equivalent dose of 7±3.25g prednisolone during the 
first 90 days after transplantation; The cohort of Lopez-Ben et al showed an osteonecrosis 
incidence of 4%, had a slightly lower cumulative steroid dosage (2.1g prednisolone at 3 
months after transplantation) compared to previously reported cohorts; Lee et al also found 
a low incidence of ONFH in renal transplantation patients at the time of 1 year post-
transplantation, which seems to be related with low cumulative steroid dosage. There is no 
known threshold dose. In clinical practice, some patients fail to benefit from daily doses as 
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low as 2.5–7.5 mg of prednisone, whereas daily doses >7.5 mg will definitively induce 
osteoporosis and osteonecrosis in the majority of patients.  
2.2.3 Main mechanism 
The mechanism of ONFH after renal transplantation includes: 1. Thrombus due to the 
steroid-induced hypercoagulable state(Hypercoagulability of plasma was found after 3 
months of steroid treatment in previous studies). 2. Reduction of blood flow in 
bone(Femoral head blood flow was 2-3 fold lower after 2 week high dose steroid treatment, 
decreased arterial inflow or increased venous outflow resistance can reduce intraosseous 
blood flow) 3. Osteoporosis of femoral(Steroid can decrease the absorption of calcium from 
intestine and increase its elimination via the kidneys. Direct and indirect effects on PTH 
secretion, changes in bone protein matrix, increased osteoclastic activity, and decreased 
protein synthesis all lead to a reduction in bone mass after renal transplantation, inhaled 
corticosteroids in doses above 1.5 mg/d may be associated with a significant reduction in 
bone density). 4. Metabolism disorder. 5. Fat embolism of femoral head. 6. Rise of 
intraosseous pressure(In the rigid intraosseous compartment, growth of fat cells may cause 
a rise in intraosseous pressure, and thereby compress the thin-walled sinusoids, with a 
subsequent decrease in bone blood flow). 7. Degenerative changes of the hip 
capsule(Degenerative changes in the arteries and arterioles of the capsule of the hip and the 
femoral head have been found in cadavers of renal transplant patients without clinical hip 
symptoms. There was thickening of the intima, gross diminution in the number and calibre 
of the vessels in the arteries of the femoral head and infarcts of subchondral bone).  
2.2.4 Other risk factors  
The type of donor, dialysis duration, acute rejection rate, and postoperative weight gain. 
The age of the graft recipients also matters. An age of less than forty years is a risk factor for 
osteonecrosis of the femoral head. 
2.3 Contradiction during the treatment 
ONFH continues to be a difficult problem to manage, especially in renal transplant 
recipients. Both the patients and surgeons were concerned about changes of renal function 
and survival of the graft. They paid little attention to the hip joint, although early signs of 
osteonecrosis were present. High doses of steroids were used in a continuous manner, 
neglecting the abnormal joint function, which hastened the deterioration of the femoral 
head. ONFH was diagnosed at a mean of 3.5 years after transplantation, it can progress to 
severe osteoarthritis and seriously impair the life quality of transplant recipients. Early hip 
joint symptoms, including progressing hip pain and joint dysfunction, always appear 9 to 19 
months after transplantation, But in most of the clinical cases, severe joint pain and 
irreversible collapse of the femoral head had already developed when the diagnosis was 
established. Furthermore, steroid-induced ONFH following transplantation tends to have 
larger necrotic areas, and bilateral involvement is more common than unilateral 
involvement. the natural history of femoral head osteonecrosis has shown evidence that a 
large majority of clinically diagnosed cases will progress to femoral head collapse. The 
treatment of ONFH depends on the staging and severity of the clinical symptoms. 
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3. Therapy methods 
3.1 Core decompression and THA 
Joint-preserving operations like core decompression cannot arrest the progression of the 
disease effectively. Total hip replacemen(THA)t is also unsuitable for younger patients 
because of their higher activity level and longer remainder of life. So Osteonecrosis of the 
femoral head continues to be a difficult problem to manage, especial in the patient with 
various kinds of renal diseases(such like IgA nephropathy, focal segmental glomerular 
sclerosis, membranous nephropathy, mesangial proliferative glomerulonephritis, crescent 
glomerulonephritis, lupus nephritis, minimal change nephropathy and renal transplantation 
after end-stage renal diseases ). Many patients with renal diseases inevitably lose the ability 
to live independently due to advanced stages of osteoarthritis.  
3.2 FVFG 
FVFG showed favorable outcomes. Compared with core decompression of femoral head, 
FVFG had a significantly lower conversion rate to total hip arthroplasty(stage II and III 
hips), because it can enhance the revascularization of bone tissue and arrest the progression 
of the necrosis. It is also an alternative method for younger patients without severe 
osteoarthritis of the hip joint. 
3.2.1 Advantages of FVFG 
The advantage of FVFG lies in the combination of femoral head decompression(Extensive 
decompression of the femoral head along with removal of necrotic bone theoretically 
interrupts the cycle of increased intraosseous pressure and ischemia and allows for 
revascularization of the femoral head), removal of necrotic bone, introduction of 
osteoinductive cancellous bone(Filling the defect with fresh cancellous bone provides both 
osteoinductive and osteoconductive stimulation of healing), and vascularized cortical bone 
support of the subchondral surface( The vascularized fibula provides a viable cortical bone 
strut to support the subchondral bone from collapse and further enhances the 
revascularization process). This procedure may benefit young patients with more advanced 
osteonecrosis of the femoral head by halting progression of collapse, prolonging reduction 
of symptoms, and postponing total hip replacement.  
3.2.2 Clinical application of FVFG 
With the emergence of microsurgical techniques, Judet et al first treated ONFH with FVFG 
in the late 1970s. The long-term results cover 68 hips in 60 patients with 18 of these classified 
as early failures requiring conversion to THA. The remaining 50 hips were followed on 
average for 18 years. Thirty-five hips scored good or very good, which corresponds to a 52% 
success rate, the data clearly show an increase in good results for patients younger than 40 
years, and an increase in the rate of failures for patients older than 40 years. Specifically, of 
the patients younger than 40 years, 80% had good and very good results, whereas of the 
patients between 40 and 50 years, only 57% had good and very good results. After systemic 
research and long-term clinical study, Urbaniak et al improved the surgical technique. The 
results for 103 consecutive hips(eighty-nine patients) that had been treated with FVFG 
because of symptomatic osteonecrosis of the femoral head were reviewed in a prospective 
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study. total arthroplasty had been performed in thirty-one hips: five (23 per cent) of the 
twenty-two that were in stage III; seventeen (43 per cent) of the forty that were in stage IV; 
and seven (32 per cent) of the twenty-two that were in stage V. Harris hip scores had 
improved at the latest follow-up evaluation, compared with the preoperative values (p < 
0.001). For the stage-II hips, the average score improved from 56 to 80 points; for the stage-
III hips, from 52 to 85 points; for the stage-IV hips, from 41 to 76 points; and for the stage-V 
hips, from 36 to 75 points. 59 percent of the hips did not limit or only slightly limited the 
patient's ability to carry out daily activities, and 62 percent did not limit or only slightly 
limited the patient's ability to work. FVFG had decreased the need for pain medication for 
86 percent of the hips that had not been subsequently treated with an arthroplasty. 
Regardless of whether or not a subsequent arthroplasty was done, 81 per cent of the patients 
(81 per cent of the hips) were satisfied with their decision to have fibular grafting.  
FVFG became widely performed in their clinical activities. Some other clinical research also 
showed good results. Zhang et al treated 56 hips in 48 patients with FVFG and followed 
patients for a mean duration of 16 months. Roughly 69.6% of femoral heads showed 
improvement on radiographs, and the Harris hip scores showed improvement ranging from 
11-13 points. Most patients had full weight-bearing ability and took part in their daily 
activities. Aldridge et al reported an 88% success rate associated with FVFG in the femoral 
heads without collapse and a success rate of 78% with subchondral collapse. The results 
showed that FVFG is the most promising technique because it had satisfactory mid-term 
and long-term outcomes. Fibular grafts have also been proven to be alternative for the post-
collapse stage of ONFH, It is also a worthwhile procedure in patients with postcollapse 
osteonecrosis. 188 patients (224 hips) who had undergone free vascularized fibular grafting, 
between 1989 and 1999, for the treatment of osteonecrosis of the hip that had led to collapse 
of the femoral head but not to arthrosis. The mean preoperative Harris hip score was 54.5 
points, and it increased to 81 points for the patients in whom the surgery succeeded; 63% of 
the patients in that group had a good or excellent result, Patients with postcollapse, 
predegenerative osteonecrosis of the femoral head appear to benefit from FVFG, with good 
overall survival of the joint and significant improvement in the Harris hip score. FVFG is a 
well accepted treatment option for all symptomatic stages of the disease ,with proper patient 
selection, middle and long-term outcomes appear promising. FVFG continues to be a 
primary treatment option to provide relief of symptoms and preserve bone stock, especially 
in the younger patient population.  
3.2.3 Attampts on the renal transplant recipients 
FVFG has been rarely systematically reported in renal transplant recipients, although ONFH 
after renal transplantation is not rare in the clinical work. Recipients with renal insufficiency 
and unstable general conditions cannot withstand the excessive blood loss and traumatic 
stress of a hip operation. Postoperative renal graft dysfunction, severe anemia, electrolyte 
disorder, and infection are life-threatening complications. Therefore, laboratory indices, 
including the HB, WBC, ESR, BUN, SCr, UA, electrolyte, 24 hours urine volume, and urine 
protein quantity, are indispensable. In addition, the CRP and  ESR should also be included 
as a nonspecific marker of the activation of the immune system in order to provide early 
signs of postoperative graft dysfunction and infection. Furthermore, the surgery should be 
rapid and less invasive. The use of toxic renal medicine should be avoided as well. Guo 
report three renal transplant recipients with ONFH who underwent FVFG in the 
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orthopedics department of Shanghai Sixth Poeple’s Hospital. Of the three cases, two cases 
showed radiographic improvement, one case showed radiographic unchanged. All the three 
cases have been living in good health and are satisfied with their joint function. The hip joint 
pain was significantly relieved and joint motion was also improved, The Harris hip score 
elevated 22 points in average, and the Visual Analogue Scale (VAS) was decreased by 37.3 
points. Their quality of life has been greatly improved and the gait can return to normal 
after positive rehabilitation training. The patients were able to walk without aid, even 
engaged in sports. After operation, the patients returned to full activities with a better 
quality of life due to normal joint and kidney function. The follow-up results demonstrated 
that FVFG is safe, effective, and feasible for transplant recipients without serious renal graft 
dysfunction, anemia, or other systemic diseases. However, the safety of the operation 
should also be attributed to proficient surgical technique, meticulous laboratory monitoring, 
and deliberate postoperative supportive treatment. 
3.2.4 Indication discussion 
According to our previous experience, indications for using FVFG to treat ONFH in patients 
after the renal transplantation include: 1) A patient younger than 50 years who is not 
suitable for total hip replacement; 2) Severe hip pain that greatly impairs daily activity; 3) 
Necrosis of the femoral head less than Steinberg stage V (osteoarthritis stage); 4) The 
recipient’s general physical condition is stable without renal graft dysfunction, serious 
anemia, metabolic disorder, or any other systemic diseases; 5) The recipient is active and in 
need of a high quality of life; 6) To take the safety of operation into account, FVFG ought to 
be performed at least one year after transplantation. 
4. Clinical example 
A 39-year-old man who was diagnosed with IgA nephropathy by renal biopsy and 
histopathological examination in January 1998. The disease developed to chronic renal 
failure six years later. The patient was maintained on hemodialysis for 10 months until 
unilateral renal transplantation in May 2005. He received steroid therapy for 18 months after 
the operation. The accumulative dose of corticosteroids was 7.5g (converted to prednisone 
dose). Tacrolimus (FK-506) 15mg per day and MMF 2.0g was also taken each day at the 
same time. He visited our hospital in November 2006 because of severe hip joint pain on the 
left side. The symptom became aggravated quickly, and the patient had to take 0.6mg 
Ibuprofen per day to maintain his daily activities. He was diagnosed with left side ONFH 
upon hip X-ray and MRI (classified as Steinberg stage III, Fig 1 a, b). A physical exam 
revealed a gait abnormality, deep inguinal region pain, positive Thomas sign, and 
Trendelenburg sign on the affected side. A decreased range of motion occurred in abduction 
and flexion. The Harris hip score was 72 points, and the VAS pain score was 80 points. All 
routine laboratory examination results were normal upon admission (shown in Table 1). 
FVFG on the left side was performed uneventfully one week later. The laboratory exam 
showed no significant change, except for a slight elevation of the WBC to 11.2×109/L on 
postoperative day 1. The body temperature rose to 37.9°C. The WBC returned to 8.6×109/L 
on day 3 and 7.4×109/L on day 7 after antibiotic treatment (intravenous Cefuroxime 3.0g 
drip bid for 3 days), and the patient’s temperature also returned to normal. The patient was 
discharged within 2 weeks in good health. No signs of infection or renal graft dysfunction 
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were discovered during the 1 year and 8 months of follow-up. The latest radiograph results 
showed improvement (Fig 1 c). The left joint pain and stiffness were significantly relieved. A 
daily pain-killer was no longer needed. The patient’s gait also returned to normal after 
positive rehabilitation training. He returned to his full activities with a better quality of life 
due to normal joint and kidney function. The Harris hip score rose to 89 points, and the VAS 
pain score decreased to 28 points. 
 
Fig. 1. (a) Preoperative radiograph (b) T1-weighted MRI (c) Radiograph 1 year and 8 months 
after FVFG showed revascularization of the necrosis area. The femoral head did not 
collapse. 
5. References 
[1] A.Y. Plafseychuk, S.Y. Kim and B.C. Park et al., Vascularized compared with 
nonvascularized fibula grafting for the treatment of osteonecrosis of the femoral 
head, J Bone Joint Surg Am 85 (2003), p. 589. 
[2] H. Hedri, M. Cherif and K. Zouaghi et al., Avascular osteonecrosis after renal 
transplantation, Transplant Proc 39 (2007), p. 1036. 
[3] J.M. Aldridge and J.R. Urbaniak, Free vascularized fibular grafting for the treatment of 
osteonecrosis of the femoral head, Tech orthop 23 (2008), p. 44.  
[4] M.E. Steinberg, G.D. Hayken and D.R. Steinberg. A quantitative system for staging 
avascular necrosis, J Bone Joint Surg Br 77 (1995), p. 34. 
[5] H.L Hoeksma, C.H.M. Van den Ende, H.K. Ronday et al., Comparison of the 
responsiveness of the Harris Hip Score with generic measures for hip function in 
osteoarthritis of the hip, Ann Rheum Dis 62 (2003), p. 935. 
[6] Holdgate, S. Asha, J. Craig et al., Comparison of a verbal numeric rating scale with the 
visual analogue scale for the measurement of acute pain, Emerg Med 15 (2003), p. 441 
[7] J.G. Heaf, Bone disease after renal transplantation, Transplantation 75 (2003), p. 315.  
[8] T.R. Mikuls, B.A. Julian and A. Bartolucci et al., Bone mineral density changes within six 
months of renal transplantation, Transplantation 75 (2003), p. 49. 
www.intechopen.com
 
Renal Transplantation – Updates and Advances 
 
212 
[9] S. Tang, T.M. Chan and S.L. Lui et al., Risk factors for avascular bone necrosis after renal 
transplantation, Transplant Proc 32 (2000), p. 1873. 
[10] W. Drescher, T. Schneider and C. Becker et al., Selective reduction of bone blood flow by 
short-term treatment with high-dose methylprednisolone, An experimental study 
in pigs. J Bone Joint Surg Br 83 (2000), p. 274.  
[11] G.S. Dean, R.C. Kime and R.D. Fitch et al., Treatment of osteonecrosis in the hip of 
pediatric patients by free vascularized fibular graft, Clin Orthop Relat Res 386 (2001), 
p. 106. 
[12] H. Judet and A. Gilbert, Long-term results of free vascularized fibular grafting for 
femoral head necrosis, Clin Orthop Relat Res 386 (2001), p. 114. 
[13] J.R. Urbaniak, P.G. Coogan and E.B. Gunneson et al., Treatment of osteonecrosis of the 
femoral head with free vascularized fibular grafting: A long-term follow-up study 
of one hundred and three hips, J Bone Joint Surg Am 77 (1995), p. 681. 
[14] C.Q. Zhang, B.F. Zeng and Z.Y. Xu, et al., Treatment of femoral head necrosis with free 
vascularized fibular grafting: a preliminary report, J Microsurg 25 (2005), p. 305. 
[15] K.R. Berend, E.B. Gunneson and J.R. Urbaniak, Free vascularized fibular grafting for the 
treatment of postcollapse osteonecrosis of the femoral head, J Bone Joint Surg Am 85 
(2003), p. 987.  
[16] A.M. Cueto-Manzano, L.E. Morales-Buenrostro and L. Gonzalez-Espinoza et al., 
Markers of inflammation before and after renal transplantation, Transplantation 80 
(2005), p. 47.  
[17] C. Reek, S. Conrad and H. Huland, The role of C-reactive protein in graft dysfunction 
after renal transplantation, J Urol 161 (1999), p. 1463. 
[18] Y. J. Guo, D. X. Jin, C.Q. Zhang, et al., Curative Effect and Safety of Vascularized Fibula 
Grafting in Renal Transplant Recipients With Osteonecrosis of the Femoral Head: 
Three Case Reports, J Transplant Proc 41(2009), P. 3731. 
[19] H. Sperschneider, G. Stein, Bone disease after renal transplantation, J Nephrol Dial 
Transplant 18(2003), P.874 
[20] E. Lee, K. Lee, W. Huh, et al., Incidence and radio-uptake patterns of femoral head 
avascular osteonecrosis at 1 year after renal transplantation: a prospective study 
with planar bone scintigraphy, J  Nuclr Med Commun 27(2006), P. 919. 
[21] T. Kubo, S. Yamazo, N. Sugano, et al., Initial MRI findings of non-traumatic 
osteonecrosis of the femoral head in renal allograft recipients. J Magn Reson Imaging 
15(1997), P. 1017. 
[22] S. B. Marston, K. Gillingham, R. F. Bailey, et al., Osteonecrosis of the femoral head after 
solid organ transplantation: a prospective study. J Bone Joint Surg Am 84A (2002), P. 
2145. 
[23] R. Lopez-Ben, T. R. Mikuls, D. S. Moore, et al., Incidence of hip osteonecrosis among 
renal transplantation recipients: a prospective study, J Clin Radiol 59(2004), P. 31. 
[24] G. S. Lausten, T. Lemser, P. K. Jensen, et al., Necrosis of the femoral head after kidney 
transplantation. J Clin Transplant 12(1998), P. 572. 
[25] K. K. Kopecky, E. M. Braunstein, K. D. Brand, et al., Apparent avascular necrosis of the 
hip: appearance and spontaneous resolution of MR findings in renal allograft 
recipients. J Radiol 179(1991), P. 523 
[26] J. Brian. Lipworth, Systemic adverse effects of inhaled corticosteroid therapy: A 
systematic review and meta-analysis, J Arch Intern Med. 159(1999), P. 941 
[27] T. Kubo. H. Tsuji H, T. Yamamoto T, et al., Antithrombin III deficiency in a patient who 
has mulitifocal osteonecrosis. J. Clin Orthop. 378(2000), p. 306 
www.intechopen.com
Renal Transplantation - Updates and Advances
Edited by Dr. Layron Long
ISBN 978-953-51-0173-4
Hard cover, 234 pages
Publisher InTech
Published online 29, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book presents a nice international compilation of scholarly papers and chapters which address the latest
advances in renal transplant surgery. These works cover a variety of topics; the last advance and success of
renal transplant science: biochemistry, immunology, molecular genetics, pharmacology - pharmacogenetics,
pediatric transplant and a few rare uropathies that warrant organ replacement.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yan Jie Guo and Chang Qing Zhang (2012). Osteonecrosis of Femoral Head (ONFH) After Renal
Transplantation, Renal Transplantation - Updates and Advances, Dr. Layron Long (Ed.), ISBN: 978-953-51-
0173-4, InTech, Available from: http://www.intechopen.com/books/renal-transplantation-updates-and-
advances/-osteonecrosis-of-femoral-head-onfh-after-renal-transplantation
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
